Page 1 - EMA e Vaccini: Linee Guida
P. 1
1 26 April 2018 March 2017
2 EMEA/CHMP/VWP/164653/05 Rev. 1
3 Committee on Human Medicinal Products (CHMP)
4
5 Guideline on clinical evaluation of vaccines
6
7 Draft
8
9
Draft Rev. 1 agreed by Vaccine Working Party (VWP)
Adopted by CHMP for release for consultation 26 April 2018
Start of public consultation 30 April 2018
End of consultation (deadline for comments) 30 October 2018
10
11 This guideline replaces ‘Guideline on the clinical evaluation of new vaccines’
12 (EMEA/CHMP/VWP/164653/05) including its ‘Annex on SPC requirements’
13 (EMEA/CHMP/VWP/382702/06) and ‘Guideline on adjuvants in vaccines for human use’
14 (EMEA/CHMP/VEG/134716/04)
15
16
Comments should be provided using this template. The completed comments form should be sent to
VWP@ema.europa.eu
17
Keywords Vaccine, humoral immune response, cellular immune response,
vaccination schedule, immunogenicity studies, protective efficacy,
effectiveness, safety, immune correlates of protection
18
30 Churchill Placeâ— Canary Wharf â— London E14 5EUâ— United Kingdom An agency of the European Union
Telephone +44 (0)20 36606000 Facsimile +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.